State of Wyoming’s Revance Therapeutics, Inc. RVNC Stock Holding History

State of Wyoming’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,261	Closed	-$239K	–	2193
2022 Q1	$239K	Buy	12,261 +3,289	+37%	+$49.9K	0.12%	136
2021 Q4	$146K	Buy	8,972 +556	+7%	+$9.27K	0.07%	383
2021 Q3	$234K	Sell	8,416 -182	-2%	-$5.19K	0.15%	126
2021 Q2	$255K	Buy	+8,598	New	+$248K	0.16%	124

Other funds holding RVNC

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State of Wyoming's RVNC Position: Q2 2022 in Review

State of Wyoming sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2022, closing a stake of 12,261 shares — an estimated $239K sold.

State of Wyoming first reported a position in RVNC in Q2 2021 and held it in 4 quarters. The position peaked at $255K in Q2 2021. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2022.

State of Wyoming reported no remaining Revance Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
State of Wyoming sold 12,261 Revance Therapeutics, Inc. shares in Q2 2022, an estimated $239K.
State of Wyoming first reported a position in Revance Therapeutics, Inc. in Q2 2021 and held it in 4 quarters.
State of Wyoming's Revance Therapeutics, Inc. position peaked at $255K in Q2 2021.
161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2022.

Based on State of Wyoming's 13F filing for Q2 2022, filed 15 Aug 2022.